|
Original-Research: NFON AG - from NuWays AG
Classification of NuWays AG to NFON AG
Q3e: Further improving top-line & profitability, chg. NFON will release Q3 figures on 21st November. Overall, we expect a solid release including further sequential improvements on top- and bottom-line. In detail: Q3 sales are seen to increase 5.4% yoy to € 21.6m on the back of imposed prices increases as well as continuous seat growth. Again, we expect an increasing share of recurring revenues of 94.6%, implying recurring revenues of € 20.4m. On the other hand, non-recurring hardware sales are seen to remain muted in Q3 with € 1.2m. With this, we expect the ARPU to come in at a solid level of € 9.94. Yet, we expect a further ARPU improvement going forward, driven by (1) the up-selling of premium solutions as well as (2) the consolidation of botario effective with Q4. On this basis, Q3 adj. EBITDA is expected to come in at € 2.9m (+10.3% yoy), implying a 13.3% margin. This should be partly driven by an improved gross margin but mainly by the imposed efficiency measures in personnel (eNuW: cost ratio down 1.9pp vs FY ’23) and especially sales & marketing (eNuW: other OpEx -1.7pp vs FY ’23). Also, FCF should again come in strong with € 1.5m (eNuW). Against this backdrop, management should confirm the FY ’24 guidance, targeting recurring revenue growth in the mid- to upper single-digit range (eNuW: +5.3% yoy), adj. EBITDA of € 10-12m (eNuW: € 11.3m) as well as a recurring revenue ratio of 90+% (eNuW: 94.3%). This should be easily achieved, in our view, given 9M ‘24e adj. EBITDA of € 8.5m as well as sequentially improving recurring revenue growth so far in 2024. Going forward, we expect the integration of DTS to offer further upside as well as the consolidation of newly acquired AI-subsidiary botario. Here, we also expect strong synergies to arise in the form of cross- and up-selling. Overall, the company remains excellently positioned to grasp the highly promising opportunities in the European market for integrated business communication, in our view. As valuation remains attractive at 8.4x EV/EBITDA ‘24e (5.5x ‘25e), wer reiterate BUY with an unchanged PT of € 11.70 based on DCF. NFON also remains one of our top-picks as part of the NuWays Alphalist. You can download the research here: http://www.more-ir.de/d/31297.pdf For additional information visit our website: www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2028591 13.11.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
